United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 5 minute read General business news Will Polyrizon’s $5.8m move into private aviation reshape its biotech-focused capital strategy? (NASDAQ: PLRZ) Polyrizon plans to buy 51% of Arrow Aviation in a $5.8M deal. Find out how this biotech-to-aviation pivot could reshape its capital strategy. bySoujanya RaviFebruary 5, 2026